RFA-TR-21-009: Screening for Conditions by Electronic Nose Technology (SCENT) (U01 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants of up to $650,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make $18.0 million in total. Applications closed on June 10, 2021.
From the official notice on Grants.gov, last changed February 3, 2021. Checked November 7, 2026.
- Award ceiling$650,000
- Total funding$18.0 million
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsOptional
- Funded byNCATS
- Median yearly award$1.2 million
- Typical project length5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-TR-21-009 were run by National Center for Advancing Translational Sciences (NCATS, 3 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-TR-21-009 in the NIH Guide.
Key dates
| Posted | February 3, 2021 |
|---|---|
| Deadline | June 10, 2021 |
| Archived by Grants.gov | July 16, 2021 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $1.2 million; it allows up to $650,000 per award.
- Most of the program's money (82% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin and to develop a catalog of VOCs as distinct signatures for at least 20 human diseases and conditions. These sensing devices must be able to associate VOC patterns using artificial intelligence to patients with various conditions for diagnostic purposes along with capabilities to incorporate and integrate vital signs. For VOC monitoring, these sensing devices can be Electronic-nose (E-nose) technology, Gas Chromatography (GC) or any sensing technology able to detect VOC patterns associated with disease. This new program is called SCENT, which stands for Screening for Conditions by E-Nose Technology. To ensure project success, this FOA requires multidisciplinary collaborations and a team science approach. Groups may include a combination of the following: Biomedical engineers, material scientists, biosensing experts, software engineers, chemists, clinicians, clinical trialists, biostatisticians, data analysts and/or other relevant experts in academia and industry.
Funded under RFA-TR-21-009 so far
NIH funded 3 projects under RFA-TR-21-009 in fiscal 2022 to 2026, at 3 institutions. The median yearly award was $1.2 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| High performance wearable body odor sensor arrays for disease detection and monitoring | University of Michigan at Ann Arbor | 2026 | $1.2 million |
| A Novel Device for Rapid and Noninvasive Volatile Metabolite-based Screening and Diagnosis of Multiple Disease States | Brigham and Women's Hospital | 2026 | $1.2 million |
| Monitoring of disease-induced skin VOC patterns from handheld and wearable chemical sensors | University of California at Davis | 2026 | $1.3 million |
Who has won National Center for Advancing Translational Sciences grants before
From fiscal 2021 to 2025, National Center for Advancing Translational Sciences (93.350) awarded $3.1 billion across 867 grant awards, an average of $3.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 15 | $95.3 million |
| Vanderbilt University Medical Center | Tennessee | 10 | $94.6 million |
| Duke University | North Carolina | 11 | $88.9 million |
| University of North Carolina at Chapel Hill | North Carolina | 16 | $74.5 million |
| The Johns Hopkins University | Maryland | 20 | $70.7 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-TR-21-009 still open?
No. It closed on June 10, 2021.
Who can apply for Screening for Conditions by Electronic Nose Technology (SCENT) (U01 Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Screening for Conditions by Electronic Nose Technology (SCENT) (U01 Clinical Trial Optional)?
Closed June 10, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $650,000 each. About $18.0 million in total.
Who has been funded under RFA-TR-21-009?
NIH RePORTER lists 3 projects funded under RFA-TR-21-009 in fiscal 2022 to 2026, at 3 institutions. The most were at University of Michigan at Ann Arbor, Brigham and Women's Hospital, University of California at Davis.
Who has won National Center for Advancing Translational Sciences grants before?
The largest recipients over five fiscal years were University of Pittsburgh - of the Commonwealth System of Higher Education, Vanderbilt University Medical Center, Duke University. The program made 867 awards worth $3.1 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)